Neurodevelopmental disorder therapy

1. A method of treating a neurodevelopmental disorder or multiple sclerosis in a subject by administering to a subject in need thereof a composition comprising a therapeutically effective amount of a therapeutic agent selected from the group consisting of Anavex2-73, ANAVEX1-41, Anavex19-144 or any combination thereof, wherein the composition is selected from an oral composition, a transdermal composition and a parenteral composition.

2. The method of claim 1 wherein the neurodevelopmental disorder is selected from the group consisting of cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith-Magenis syndrome, Rett syndrome, and autism spectrum disorder.

3. The method of claim 1 , wherein the therapeutic agent is Anavex2-73.

4. The method of claim 1 , wherein the therapeutically effective amount is a dosage from about 0.5 mg/day to about 100 mg/day.

5. The method of claim 1 , wherein the subject is an adult, a child, or an infant.

6. The method of claim 5 , wherein the subject is an adult and the dosage ranges from about 20 mg/day to about 50 mg/day.

7. The method of claim 5 , wherein the subject is a child or an infant and the dosage ranges from about 0.5 mg/day to about 20 mg/day.

8. The method of claim 1 , wherein the composition is orally administered as an oral composition.

9. The method of claim 8 , wherein the oral composition comprises a bulk liquid solution, a bulk liquid suspension, or a bulk powder.

10. The method of claim 9 , wherein the bulk liquid solution or bulk liquid suspension comprises at least one aqueous or nonaqueous carrier or vehicle, and at least one processing aid.

11. The method of claim 9 , wherein the bulk powder comprises at least one pharmaceutically acceptable excipient.

12. The method of claim 8 , wherein the therapeutically effective amount of the therapeutic agent in the oral composition ranges from about 0.1 wt % to about 50 wt % of the composition.

13. The method of claim 1 , wherein the composition is transdermally administered as a transdermal composition.

14. The method of claim 13 , wherein the therapeutically effective amount of the therapeutic agent in the transdermal composition ranges from about 0.01 wt % to about 20.0 wt % of the composition.

15. The method of claim 13 , wherein the transdermal composition is an ointment comprising at least one of a paraffinic ointment base and a water-miscible ointment base.

16. The method of claim 13 , transdermal composition is a cream comprising an oil-in-water cream base.

17. The method of claim 13 , wherein the transdermal composition comprises at least one of a dermal penetration-enhancing agent and a composition stability-enhancing agent.

18. The method of claim 13 , wherein administering the transdermal composition comprises use of a transdermal device.

19. The method of claim 18 , wherein the transdermal device comprises a transdermal patch.

20. The method of claim 19 , wherein the transdermal patch is selected from a reservoir membrane type patch, a porous membrane type patch, or a solid matrix type patch.

21. The method of claim 1 , wherein the composition is administered parenterally as a parenteral composition.

22. The method of claim 21 , wherein the parenteral composition comprises from about 0.05 wt % to about 10.0 wt % of the therapeutic agent.

23. The method of claim 22 , wherein the parenteral composition further comprises at least one pharmaceutically acceptable carrier.

24. The method of claim 1 , wherein the administration lasts for a period of at least 10 days.